JP7371009B2 - キメラベクター - Google Patents

キメラベクター Download PDF

Info

Publication number
JP7371009B2
JP7371009B2 JP2020558967A JP2020558967A JP7371009B2 JP 7371009 B2 JP7371009 B2 JP 7371009B2 JP 2020558967 A JP2020558967 A JP 2020558967A JP 2020558967 A JP2020558967 A JP 2020558967A JP 7371009 B2 JP7371009 B2 JP 7371009B2
Authority
JP
Japan
Prior art keywords
vector
human
protein
seq
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020558967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523695A5 (https=
JP2021523695A (ja
Inventor
ムニル、シリン
ジー． ブロック、リンダ
ジェイ． ブッフホルツ、ウルスラ
エル． コリンズ、ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2021523695A publication Critical patent/JP2021523695A/ja
Publication of JP2021523695A5 publication Critical patent/JP2021523695A5/ja
Priority to JP2023179912A priority Critical patent/JP2024020214A/ja
Application granted granted Critical
Publication of JP7371009B2 publication Critical patent/JP7371009B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18541—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18541—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18543—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18541—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18544—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020558967A 2018-04-23 2019-04-23 キメラベクター Active JP7371009B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023179912A JP2024020214A (ja) 2018-04-23 2023-10-18 キメラベクター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661320P 2018-04-23 2018-04-23
US62/661,320 2018-04-23
PCT/US2019/028771 WO2019209859A1 (en) 2018-04-23 2019-04-23 Chimeric vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023179912A Division JP2024020214A (ja) 2018-04-23 2023-10-18 キメラベクター

Publications (3)

Publication Number Publication Date
JP2021523695A JP2021523695A (ja) 2021-09-09
JP2021523695A5 JP2021523695A5 (https=) 2022-05-06
JP7371009B2 true JP7371009B2 (ja) 2023-10-30

Family

ID=66794071

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020558967A Active JP7371009B2 (ja) 2018-04-23 2019-04-23 キメラベクター
JP2023179912A Pending JP2024020214A (ja) 2018-04-23 2023-10-18 キメラベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023179912A Pending JP2024020214A (ja) 2018-04-23 2023-10-18 キメラベクター

Country Status (10)

Country Link
US (2) US12071632B2 (https=)
EP (1) EP3784788A1 (https=)
JP (2) JP7371009B2 (https=)
KR (1) KR20210005090A (https=)
CN (1) CN112262215B (https=)
AU (1) AU2019261570B2 (https=)
BR (1) BR112020021652A2 (https=)
CA (1) CA3097888A1 (https=)
TW (2) TW202440937A (https=)
WO (1) WO2019209859A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN114685627A (zh) * 2020-12-28 2022-07-01 广州更新生物医药科技有限公司 一种预防呼吸道合胞病毒的rAAV载体疫苗
WO2024238911A1 (en) * 2023-05-17 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant murine pneumonia virus expressing severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike protein

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530073A (ja) 1999-07-09 2003-10-14 アメリカ合衆国 弱毒化されたヒト−ウシキメラ呼吸器合胞体ウィルスワクチンの製造
JP2004531220A (ja) 2001-01-19 2004-10-14 ヴィロノヴァティブ，ベスローテン ヴェンノートシャップ 感受性哺乳動物において気道疾患を引き起こすウイルス
JP2008518602A (ja) 2004-10-28 2008-06-05 セントカー・インコーポレーテツド 抗呼吸器多核体ウイルス抗体、抗原、およびそれらの用途
JP2018503402A (ja) 2015-01-20 2018-02-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ キメラｒｓｖ／ｂｐｉｖ３ ｆタンパクを発現する組換えヒト／ウシパラインフルエンザウイルス３（ｂ／ｈｐｉｖ３）およびその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
LT2285408T (lt) * 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530073A (ja) 1999-07-09 2003-10-14 アメリカ合衆国 弱毒化されたヒト−ウシキメラ呼吸器合胞体ウィルスワクチンの製造
JP2004531220A (ja) 2001-01-19 2004-10-14 ヴィロノヴァティブ，ベスローテン ヴェンノートシャップ 感受性哺乳動物において気道疾患を引き起こすウイルス
JP2008518602A (ja) 2004-10-28 2008-06-05 セントカー・インコーポレーテツド 抗呼吸器多核体ウイルス抗体、抗原、およびそれらの用途
JP2018503402A (ja) 2015-01-20 2018-02-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ キメラｒｓｖ／ｂｐｉｖ３ ｆタンパクを発現する組換えヒト／ウシパラインフルエンザウイルス３（ｂ／ｈｐｉｖ３）およびその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bennett N. et al.，Expert Rev Vaccines，2007年，Vol. 6，pp. 169-182
Haller A A. et al.，J Gen Virol，2003年，Vol. 84，pp. 2153-2162
Krempl C D. et al.，J Virol，2007年，Vol. 81，pp. 9490-9501
Liang B. et al.，J Virol，2014年，Vol. 88，pp. 4237-4250

Also Published As

Publication number Publication date
US20210189425A1 (en) 2021-06-24
US20240392317A1 (en) 2024-11-28
CA3097888A1 (en) 2019-10-31
EP3784788A1 (en) 2021-03-03
BR112020021652A2 (pt) 2021-02-02
TW202440937A (zh) 2024-10-16
JP2021523695A (ja) 2021-09-09
KR20210005090A (ko) 2021-01-13
CN112262215B (zh) 2025-03-18
AU2019261570A1 (en) 2020-11-19
AU2019261570B2 (en) 2025-06-05
WO2019209859A8 (en) 2019-12-19
JP2024020214A (ja) 2024-02-14
US12071632B2 (en) 2024-08-27
TWI848944B (zh) 2024-07-21
AU2019261570A2 (en) 2020-11-26
TW202012629A (zh) 2020-04-01
CN112262215A (zh) 2021-01-22
WO2019209859A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
JP2024020214A (ja) キメラベクター
AU2005318087B2 (en) Rescue of influenza virus
US10494613B2 (en) Generation of infectious influenza viruses from virus-like particles
Liang et al. Packaging and prefusion stabilization separately and additively increase the quantity and quality of respiratory syncytial virus (RSV)-neutralizing antibodies induced by an RSV fusion protein expressed by a parainfluenza virus vector
JP2023524990A (ja) ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用
US20240366751A1 (en) Coronavirus vaccine
US20250228929A1 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
US20250041402A1 (en) Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof
EP4295862A2 (en) Coronavirus vaccine
CN117899208A (zh) 冠状病毒疫苗
US20230279362A1 (en) Live attenuated respiratory syncytial virus
US20240148857A1 (en) Recombinant rsv vaccine: methods of making and using the same
WO2026080706A1 (en) Recombinant chimeric bovine/human parainfluenza virus 3 expressing avian influenza virus proteins and use thereof
Lamichhane Development of a Live Respiratory Syncytial Virus Vaccine with Attenuation Based on Single-Cycle Replication
WO2025147639A1 (en) Improved formulation providing increased stability for vaccines composition
JP2026504603A (ja) 修飾ｐｉｖ５ワクチンベクター：作製方法及び使用方法
WO2025054424A1 (en) Human parainfluenza virus immunogenic molecules

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20210120

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210122

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20210120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231018

R150 Certificate of patent or registration of utility model

Ref document number: 7371009

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150